Fusion protein · Immune activation, directed at CD47 and CD40 · developed by Shattuck Labs
SL-172154 is a fusion protein made of the extracellular domains of human SIRPα and CD40 ligand linked through a human Fc domain. It binds CD47 on tumor cells, blocking the CD47/SIRPα interaction that inhibits macrophage phagocytosis, and binds CD40 on antigen-presenting cells to activate them. It is studied in squamous cell carcinomas of the head and neck and skin, acute myeloid leukemia, and myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05275439 | Phase 1 | Acute Myeloid Leukemia | Terminated | STTK |
| NCT04502888 | Phase 1 | Cutaneous Squamous Cell Carcinoma | Terminated | STTK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaCutaneous Squamous Cell CarcinomaMyelodysplastic SyndromesSquamous Cell Carcinoma of Head and Neck
Updated Nov 1, 2026. Something wrong or missing? Report it on the STTK page.
See STTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STTK catalysts and pipeline →